modulation of 5-fluorouracil (5-FU) [1] [2] [3] [4] . In S-1, tegafur (FT) is combined with two classes of enzyme inhibitor, 5-chloro-2, 4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo), at a molar ratio of FT : CDHP : Oxo ϭ 1: 0.4 : 1 [5] . S-1 achieved a response rate of 44.6% (45/101) in gastric cancer patients in late phase II studies [6, 7] . On the strength of such excellent results in phase II studies, gastric cancer as an indication for the use of S-1 was permitted, in March 1999, and its commercial use became possible.
Introduction
Oral fluoropyrimidines, which hold the most important position in chemotherapy on an outpatient basis for gastric cancer, are widely used for advanced disease and as adjuvant chemotherapy. S-1, a new oral antitumor agent, was designed based on the theory of biochemical fluoropyrimidines (DIF), were useful in the treatment of patients with low DPD activity and that S-1 was especially useful in patients with high DPD activity. Fujiwara, who conducted a basic study using nude mice, reported on the selection of indications for oral fluoropyrimidines in view of thymidylate synthase (TS), DPD, and thymidine phosphorylase (TP) enzyme activities.
Clinical results of treatment with S-1 alone: five papers
Cho, Kawai, and Yoshida reported the results of clinical practice in the treatment of gastric cancer with S-1 alone. Cho reported a survival benefit among patients who received longterm administration of S-1. Kawai reported that patients who received an initial dose of S-1 showed a 2-year survival rate of 35%, indicating the high efficacy of S-1. Yoshida emphasized that treatment with S-1 alone produced better results than treatment with a low dose of cisplatin (CDDP) plus 5-FU at his facility. Yoshida also indicated the possibility of personalized chemotherapy, based on an efficacy prediction model using a statistical technique. Table 2 shows a summary of the response rates and median survival times (MSTs) of these three reports.
Imamura reported on the results of a clinical study for curing gastric cancer with S-1 alone and suggested a modified schedule to reduce adverse reactions. Kinoshita reported a pilot study of preoperative chemotherapy with S-1 for scirrhous gastric cancer. Given these study results, the Japan Clinical Oncology Group (JCOG) is currently carrying out a phase II study of S-1 preoperative chemotherapy for scirrhous gastric cancer.
S-1 therapy combined with other drugs: two papers
Takahashi reported the results of a study on the antitumor effect and toxicity of combination chemotherapy of S-1 with docetaxel using nude rats. An increased antitumor effect in the slight toxicity range was demonstrated. Baba reported the therapeutic outcome for advanced gastric cancer patients treated with a combination of S-1 and CDDP. According to the Ohtsu regimen [8] , S-1 was administered orally at 80 mg/m 2 per day twice a day for 21 consecutive days and CDDP was infused at 60 mg/m 2 over 2 h on day 8. An assessment of nine evaluable cases showed a response rate of 56%. Baba stated that this combination therapy was the first choice for patients with advanced or recurrent gastric cancer and that it was suitable for preoperative chemotherapy.
Finally, Kaibara gave a special lecture. He reported an investigation of the relationship between the prognosis of patients who received oral fluoropyrimidines as postoperative adjuvant chemotherapy and the prognosis of those who also received 5-FU metabolic and catabolic enzymes. He presented results for some patients who responded to S-1 and also described the prospects for future S-1 chemotherapy.
General presentations
In the "General presentations," 26 papers on S-1 related subjects were presented in posters (Table 3) . Twelve papers were about the clinical study of S-1 alone or the results of clinical practice with S-1. Three papers were case reports, including the report of a patient with a complete response to S-1. Nearly all the papers described the clinical effects of S-1 on advanced or recurrent gastric cancer, suggesting the usefulness of S-1 in patients with advanced or recurrent gastric cancer. Fujitani et al. reported on the safety and efficacy of S-1 for stage IV cancer, and showed the possibility that S-1 contributes to the survival of patients when used in adjuvant chemotherapy for stage IV gastric cancer. There were two reports of basic studies, both about S-1 in animal models of peritoneal metastasis. Mori demonstrated the usefulness of S-1 for peritoneal dissemination, using an experimental model of peritoneal dissemination of gastric cancer. Mochizuki et al. presented an experimental study in a model of peritoneal dissemination of green fluorescent protein (GFP)-tagged human gastric cancer. They reported that the inhibitory effect of S-1 on peritoneal disseminated metastasis improved as the number of viable cancer cells in the peritoneal cavity decreased, and that S-1 improved survival prognosis if the number of cancer cells was small.
Papers on combination chemotherapy with S-1 included six reports on the results of clinical studies or the results of clinical practice at individual medical centers, and three case reports. Combination chemotherapy involved S-1 ϩ CDDP in seven reports (the majority), S-1 ϩ irinotecan (CPT-11) in one report, and 5-FU ϩ Table 3 
. S-1 related reports in General Presentations
No.
Title Reporter P-042 Experience of chemotherapy using S-1 for advanced and recurrent gastric cancer Nakamura P-063 A case of advanced gastric cancer improved by S-1 Nagai P-064
Clinical efficacy of S-1 for treatment of advanced gastric cancer Nakamura P-065 A case of advanced gastric cancer treated with S-1 and CPT-11 Yamashita P-075
Preoperative chemotherapy with S-1 and low dose CDDP for advanced gastric cancer Saikawa P-078
Effect of administration of CPT-11 combined with CDDP on S-1 tolerated gastric cancer Sugiura P-079 FLEP/S-1 therapy for advanced gastric cancer Mochizuki P-080
Effectiveness of S-1 for gastric cancer: emphasis on effective cases Sato P-081
Clinical effect and adverse reactions of S-1 administration before surgery for advanced gastric Chochi cancer P-082 S-1/CDDP therapy for advanced gastric cancer Nakamura P-083
Chemotherapy with S-1 and CDDP for advanced gastric cancer Michiura P-084
The effect of S-1 and combined chemotherapy of CDDP/S-1 for highly advanced gastric cancer Konno P-090
New therapeutic experience of S-1 for reduction of adverse reactions Kimura P-091
A case of gastric cancer with liver metastasis and LN metastasis treated with S-1/CDDP Maruyama P-167
Evaluation of the efficacy of S-1 on peritoneal metastasis of gastric cancer using an animal model Mori P-168
Inhibition of peritoneal micrometastasis of GFP-tagged gastric cancer cells by S-1 Mochizuki P-175
Effects of S-1 on recurrent gastric cancer and consideration of the indications for administration Yamada P-185
Umbilical metastasis of gastric cacer Nakasato P-187
A case in which S-1ϩCDDP therapy worked effectively on DIC due to multiple bone Yoshioka metastasis of gastric cancer P-238
Home therapy using S-1 in combination with enteral nutrition support for gastric cancer patients Sano P-279
Successful treatment for gastric cancer associated with multiple liver metastases with S-1 Suzuki followed by curative gastrectomy P-280
Three cases with effective response to S-1 for inoperable gastric cancer Urano P-281 Improvement in the survival of patients with advanced gastric cancer by S-1 Watanabe P-282
Significance of S-1 for advanced or recurrent gastric cancer Ohashi P-283
A clinical study of S-1 in patients with advanced and recurrent gastric cancer 
Summary and future prospects
The S-1-related studies presented at the 74th Japanese Gastric Cancer Congress have been summarized. Several studies showed that S-1 was generally as effective against tumors in the postmarketing surveillance in clinical practice as in phase II studies at the time of its development. Because S-1 is an oral preparation, it can be used on an outpatient basis and should be beneficial from the viewpoint of the patient's quality of life (QOL). These results indicate that S-1 is a key drug that can be used in the first-line treatment of gastric cancer. Some reports suggested the possibility of using S-1 in neoadjuvant chemotherapy and postoperative adjuvant chemotherapy. Thus, it is necessary to verify the usefulness of S-1 in a large-scale prospective randomized trial. The usefulness of S-1 in combination chemotherapy was also suggested by several reports, although only preliminary results have been obtained so far. Further clinical studies must be conducted to establish combination chemotherapy involving S-1, CDDP, CPT-11, paclitaxel, and docetaxel. Because S-1 is expected to become the standard drug for the treatment of gastric cancer, it will be necessary to build up evidence by further accumulation of data from clinical trials and clinical practice in the future.
